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Abstract
Purpose Since the success of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging for
patients with oligorecurrent prostate cancer (ORPC), it is increasingly used for radiotherapy as metastasis-directed therapy
(MDT). Therefore, we developed a prognostic risk classification for biochemical relapse-free survival (bRFS) for patients after
PSMA-PET-guided MDT after radical prostatectomy.
Methods We analyzed 292 patients with local recurrence (LR) and/or pelvic lymph node (LN) lesions and/or up to five distant
LN, bone (BM), or visceral metastases (VM) detected with [68Ga]PSMA-PET imaging. Median follow-up was 16 months (range
0–57). The primary endpoint was bRFS after MDT. Cox regression analysis for risk factors was incorporated into a recursive
partitioning analysis (RPA) with classification and regression tree method.
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Results PSA at recurrence ≥ 0.8 ng/mL, BM, and VM was significantly associated with biochemical relapse. RPA showed five
groups with tenfold cross-validation of 0.294 (SE 0.032). After building risk classes I to IV (p < 0.0001), mean bRFS was
36.3 months (95% CI 32.4–40.1) in class I (PSA < 0.8 ng/mL, no BM) and 25.8 months (95% CI 22.5–29.1) in class II (PSA
≥ 0.8 ng/mL, no BM, no VM). LR and/or pelvic LNs caused relapse in classes I and II. Mean bRFS was 16.0 months (95% CI
12.4–19.6) in class III (PSA irrelevant, present BM) and 5.7 months (95% CI 2.7–8.7) in class IV (PSA ≥ 0.8 ng/mL, no BM,
present VM).
Conclusion We developed and internally validated a risk classification for bRFS after PSMA-PET-guided MDT. Patients with
PSA < 0.8 ng/mL and local relapse only (LR and/or pelvic LNs) had the most promising bRFS. PSA ≥ 0.8 ng/mL and local
relapse only (LR and/or pelvic LNs) indicated intermediate risk for failure. Patients with BMwere at higher risk regardless of the
PSA. However, those patients still show satisfactory bRFS. In patients with VM, bRFS is heavily decreased. MDT in such cases
should be discussed individually.
Keywords Prostate-specific membrane antigen-positron emission tomography . Prostatic carcinoma . Oligometastatic .
Oligorecurrent .MDT
Introduction
In 1995, Weichselbaum et al. hypothesized that an
oligometastatic state in cancer progression exists [1]. On that
basis, the oligorecurrent paradigm was also introduced into pros-
tate cancer (PC) management. However, several descriptions of
oligometastatic PC exist, and definitions vary between less than
three to five distant lesions [2]. Data show a better outcome for
patients with oligometastatic PC than for patients with advanced
metastatic disease [3]. Recently, Ost et al. demonstrated that pa-
tients with oligorecurrent PC treated with metastasis-directed
therapy (MDT) had improved freedom from androgen depriva-
tion therapy (ADT) (13 vs. 21 months) [4]. Furthermore,
Decaestecker et al. reported a prolonged time to ADT and no
grade III toxicity after repeated stereotactic body radiotherapy
(SBRT) [5]. Interestingly, even by using less sensitive choline
positron emission tomography (PET) imaging for staging in the
trials mentioned above [4, 5], a good response to MDT was
observed.
Nevertheless, standard-of-care treatment for oligorecurrent
PC remains empiric salvage radiotherapy (RT) for suspect
local recurrence in the prostatic bed or ADT for patients with
distant metastases. Due to limited treatment and diagnostic
options, local therapy of the metastatic sites has been rarely
used in the past. With the increasing application of prostate-
specific membrane antigen (PSMA)-PET imaging, the treat-
ment of patients with few metastases has changed. PSMA-
PET imaging has become an effective tool for staging and
defining targets for precise treatment of patients with bio-
chemical relapse after radical prostatectomy (RP) [6, 7].
Whereas in the past, radiation oncologists had to administer
empiric treatment to the prostate bed mostly without evidence
in imaging; today, PSMA-PET helps to visualize recurrent
tumor sites and distant lesions and provides a highly sensitive
means for estimating the accurate tumor load.
PSMA-PET imaging enriches the possibilities of MDT
with conventional fractionated RT, stereotactic body RT
(SBRT), or surgery. These can prolong time to initiation of
ADT [2] and bear the possibility of cure.
Up to now, the optimal selection of patients for MDT is
unknown. The majority of patients will develop progression,
despite PSMA-PET staging and MDT. Therefore, clinical risk
classifications have become an accepted instrument for
weighing the risk-benefit ratio. To our knowledge, no such
tools have been published for patients with oligorecurrent
PC treated with MDT using highly sensitive PSMA-targeted
imaging. In the present analysis, we aimed to develop a prog-
nostic risk classification predicting biochemical relapse-free
survival (bRFS) after PSMA-PET-guided MDT for
oligorecurrent prostate cancer after prior RP.
Material and methods
Patients
We established a multi-institutional, retrospective database,
and collected data of 379 patients from six German and
Swiss centers. The institutional review boards of all partici-
pating centers approved the study (BASEC-Nr. 2017-01499).
The subjects were free from distant metastases (M0) at initial
diagnosis. We defined the relapse as biochemical failure and
recurrence diagnosed by PSMA-PET imaging. The patients
exhibited oligorecurrent disease with local recurrence and/or
pelvic lymph node lesions (N1) and/or distant metastases
(M1a/1b/1c) in PSMA-PET imaging. We included patients
with up to five distant lymph node, bone, or visceral lesions
and any PSA level at PSMA-PET-based diagnosis. There was
no restriction on the total number of pelvic lymph node le-
sions. The database included patients treated with MDT for
PC metastases independently of the primary therapy. In the
present analysis, we included 292 patients with initial RP and
a subsequent diagnosis of oligorecurrent PC with positive
findings in PSMA-PET imaging. Patients with other primary
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therapy for PC (e.g., primary RT) or with previous postoper-
ative non-PSMA-PET-based RTwere exclude from this anal-
ysis (n = 87). The flow diagram is shown in Fig. 1.
PSMA-PET imaging and RT
Each patient received PET imaging with a [68Ga]-labeled
PSMA targeting ligand [8]. Imaging was performed according
to the joint EANM and SNMMI guidelines [9]. PSMA-PET
imaging was acquired in conjunction with either computed
tomography (CT) or magnetic resonance imaging (MRI).
The CT was performed as a diagnostic CT or as a low-dose
CT. Intravenous and if necessary oral iodinated contrast agents
were used if the patients had no contraindications. CT scans
were acquired in the portal venous phase. MRI scans where
performed with contrast agents, when possible. PET scans
were conducted approximately 60 min after bolus injection
of the ligand (mean activity 162.5 MBq; range 87.0–
291.0 MBq). When possible, furosemide 20 mg was given
to reduce tracer collection in the urinary tract system. One
specialist in nuclear medicine and one radiologist or a dual
boarded nuclear medicine physician and radiologist
interpreted the acquired imaging. Focal tracer uptake higher
than the surrounding background and not associated with
physiologic uptake was considered as malignant.
MDT as conventional fractionated RT or SBRT was per-
formed at the discretion of the study centers. Furthermore,
ADTwas administered according to the guidelines of the par-
ticipating departments.
Endpoints
The primary endpoint was bRFS, which was measured from
MDT to biochemical relapse. We defined biochemical relapse
as PSA levels ≥ 0.2 ng/mL above PSA nadir after RT. When
PSA levels did not respond to RT, pre-RT PSA level with a
rise of ≥ 0.2 ng/mL was defined as a relapse. Follow-up was
performed according to institutional protocol.
Statistical analysis
We applied univariate and multiple Cox regression to assess
significance for risk factors for biochemical relapse.We evaluated
initial tumor stage [10] (T2c ≤ vs. ≥T3a), initial nodal status [11]
(N0 vs. N1), initial Gleason score [10, 11] (7a ≤ vs. ≥ 7b), and
initial resection status [11] (R0 vs. R1). Further, we evaluated the
risk factors PSApersistence > 0.1 ng/mL after RP [12], PSA level
at PMSA-PET imaging/recurrence [10, 11], age at relapse as well
as the PSMA-PET-related factors local recurrence (no vs. yes),
pelvic lymph node lesions (no vs. yes), distant metastases (no vs.
yes), and the number of lesions at PSMA-PET imaging.We used
receiver operating characteristic (ROC) analysis to determine cut-
off values for non-dichotomous variables. To account for the
possible confounder of additive ADTadministration and to show
robustness of the model, multiple Cox regression was calculated
unadjusted and adjusted for additive ADT. Risk factors which
showed significance in both models were included into the risk
classification.We used recursive partitioning analysis (RPA) with
the classification and regression tree (CRT)method to analyze the
significant factors. bRFS at 12 months was the primary endpoint
in the decision tree calculation. Decision tree analysis is a non-
parametric automatic statistical learning algorithm that combines
variables. The results are shown in a decision tree with splits
based on the variables. The Gini index was applied to minimize
node impurity after splitting. End nodes of the decision tree were
grouped from A to E. For internal validation, we used tenfold
cross-validation. In the tenfold cross-validation scheme, patients
were randomly assigned into ten equal subgroups. Nine subsets
were utilized as a training cohort. The tenth group was used as a
validation set to test the performance. Subsequently, risk classes I
to IV (low to very high risk) were built by combining end node
groups with a similar outcome in Kaplan-Meier estimator for the
overall group. We used the Kaplan-Meier method to calculate
bRFS of the risk classes. All statistical analyses were performed
Fig. 1 Flow diagram of included
patients (MDT, metastasis-
directed therapy; PC, prostate
cancer; RP, radical prostatectomy;
RT, radiotherapy)
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with SPSS version 21 (IBM, Armonk, USA). A p value of less
than 0.05 was defined as statistically significant.
Results
All patients were treated for oligorecurrent PC with conventional
fractionated RT and/or SBRT between April 2013 and January
2018. The median age of all patients was 70 years (range 46–
95 years).Median follow-upwas 16months (range 0–57months).
Table 1 shows the patient characteristics, and Table 2 shows the
numbers of biochemical relapse and local control.
Table 3 shows the results of the univariate Cox regression
of prognostic factors affecting bRFS. ROC analysis deter-
mined 0.8 ng/mL as the significant cutoff value for PSA be-
fore RT. A PSA persistence after RP ≥ 0.1 ng/mL, PSA levels
prior to RT ≥0.8 ng/mL, the presence of bone metastases, and
the presence of visceral lesions were significantly associated
with relapse in the univariate analysis. Multiple Cox regres-
sion unadjusted and adjusted for additive ADT is shown in
Table 4. PSA levels ≥ 0.8 ng/mL, the presence of bone metas-
tases, and the presence of visceral metastases remained signif-
icant factors in both models.
We included the three significant factors of both models
into the RPA using the CRT method. Figure 2 shows the
decision tree with the end nodes A to E. Tenfold cross-
validation demonstrated a risk for miscalculation of 0.294
(standard error 0.032), which results in 70.6% accuracy.
The Kaplan-Meier estimator showed a mean bRFS of
36.3 months (95% CI 32.4–40.1 months) for group A (PSA <
0.8 ng/mL, no bone lesions), of 25.8 months (95% CI 22.5–
29.1months) for groupB (PSA≥ 0.8 ng/mL, no bone or visceral
lesions), of 15.6 months (95% CI 11.3–20.0 months) for group
C (PSA < 0.8 ng/mL, present bone lesions), of 16.6 months
(95% CI 11.2–22.0 months) for group D (PSA ≥ 0.8 ng/mL,
present bone lesions), and of 5.7 months (95% CI 2.7–
8.7 months) for group E (PSA ≥ 0.8 ng/mL, no bone lesions,
present visceral lesions). Subsequently, we built risk
classes with a similar outcome: risk class I with low
risk (group A), class II with intermediate risk (group
B), class III with high risk (groups C and D), and class
IV with very high risk (group E).We used the Kaplan-Meier
estimator to compare survival among risk classes for the over-
all group (see Fig. 3). The log-rank test showed significant
differences among groups with p < 0.0001.
The risk classification showed that patients with PSA levels
< 0.8 ng/mL and no bonemetastases according to PSMA-PET
experience low risk (class I). Patients diagnosed with PSA
levels ≥ 0.8 ng/mL and no bone metastases nor visceral me-
tastases prior to MDT were at intermediate risk (class II).
PSMA-PET-positive local recurrence and/or pelvic lymph
node lesions caused the PSA rise in those two classes.
Patients with bone metastases before MDT independently of
Table 1 Patient characteristics (n = 292)
All patients
(n = 292) n (%)
Initial tumor classification
pT1c 1 (0.3%)
pT2a 9 (3.1%)
pT2b 10 (3.4%)
pT2c 96 (32.9%)
pT3a 71 (24.3%)
pT3b 96 (32.9%)
pT4 9 (3.1%)
Initial nodal status
Negative 185 (63.4%)
Positive 95 (32.5%)
Missing 12 (4.1%)
Gleason score
6 16 (5.5%)
7a 67 (22.9%)
7b 86 (29.5%)
≥ 8 123 (42.1%)
Surgical margin
Negative 161 (55.1%)
Positive 131 (44.9%)
Parameters at PSMA-PET-based diagnosis of oligorecurrent disease
Median age at PSMA-PET imaging (years) 70 (range 46–95)
Median PSA level at PSMA-PET imaging
(ng/mL)
0.95 (range 0.04–40.13)
Local recurrence at PSMA-PET imaging
No 163 (55.8%)
Yes 129 (44.2%)
Pelvic lymph node metastases at PSMA-PET imaging
Negative 135 (46.2%)
Positive 157 (53.8%)
Distant metastases at PSMA-PET imaging
Lymph nodes (M1a)
No 267 (91.4%)
Yes 25 (8.6%)
Bone (M1b)
No 247 (84.6%)
Yes 45 (15.4%)
Visceral (M1c)
No 289 (99.0%)
Yes 3 (1.0%)
Median total number of PET-positive lesions 1 (range 1–19)
Pelvic lymph node lesions 1 (range 1–19)
Distant metastases 1 (range 1–5)
RT Technique
Conventional fractionated RT 265 (90.8%)
SBRT 17 (5.8%)
Conventional fractionated RT + SBRT 10 (3.4%)
Elective RT to prostate bed or locoregional lymph nodes
No 72 (24.7%)
Yes 220 (75.3%)
Median EQD2/1.5 Gy (Gy)
Prostatic fossa 66.0 (range 47.5–70.0)
Pelvic lymphatic pathways 47.5 (range 42.0–56.0)
PET-positive local recurrence 70.0 (range 57.7–83.0)
PET-positive lymph nodes 60.0 (range 46.0–85.0)
Bone lesions 56.0 (range 40.0–108.6)
Visceral lesions 108.6 (range
103.0–162.0)
Additive ADT
No 178 (61.0%)
Yes 114 (39.0%)
Median follow-up (months) 16 (range: 0–57)
PSMA-PET, prostate-specific membrane antigen-positron emission to-
mography; PSA, prostate-specific antigen; RT, radiotherapy; SBRT, ste-
reotactic body radiotherapy; EQD2/1.5Gy, equivalent dose in 2 Gy for
alpha/beta of 1.5 Gy; ADT, androgen deprivation therapy
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the PSAvalue showed a faster relapse (class III). Patients with
a PSA level ≥ 0.8 ng/mL, no bone metastases, and the pres-
ence of visceral metastases were at very high risk for de-
creased bRFS (class IV). Table 5 shows the risk classes with
the respective bRFS and a description of the prognostic fac-
tors. Distribution, duration, and medication of additive ADT
use in the risk classes are shown in Table 6.
Discussion
The present analysis aimed to develop a prognostic risk classifi-
cation for bRFS after PSMA-PET-guided MDT for patients with
oligorecurrent PC. Three variables emerged as prognostic factors
for decreased bRFS in multiple Cox regression: PSA level ≥
0.8 ng/mL, presence of bone metastases and visceral lesions.
Table 2 Number of biochemical
relapse and in-field local control Biochemical relapse
Biochemical relapse at 12 months
Yes 19.5% (57/292)
No 47.9% (140/292)
No information 2.1% (6/292)
Censored 30.5% (89/292)
Overall biochemical relapse
Yes 29.8% (87/292)
No 68.1% (199/292)
No information 2.1% (6/292)
In-field local control
Local recurrence 96.4% (53/55), missing information on 40 lesions
Pelvic lymph nodes 96.0% (145/151), missing information on 48 lesions
Bone lesions 100% (32/32), missing information on nine lesions
Visceral lesions 100% (2/2), missing information on one lesion
Patients with missing information on lesions received no imaging due to no biochemical relapse
Table 3 Univariate Cox
regression of prognostic factors
for biochemical relapse
Factors Univariate Cox regression
HR 95% CI p
Initial tumor stage (T2c ≤ vs. ≥ T3a) 0.67 0.43–1.05 0.08
Initial nodal status (N0 vs. N1) 0.67 0.43–1.05 0.08
Initial Gleason score (7a ≤ vs. ≥ 7b) 0.66 0.39–1.08 0.10
Initial resection status (R0 vs. R1) 1.02 0.67–1.58 0.91
PSA persistence > 0.1 ng/mL after RP (yes vs. no) 1.59 1.04–2.43 0.03*
PSA level at PMSA-PET imaging (> 0.8 ng/mL vs. ≤ 0.8 ng/mL) 0.51 0.32–0.79 0.003*
Age at relapse (continuous) 1.00 0.98–1.03 0.90
Local recurrence at PSMA-PET imaging (no vs. yes) 1.46 0.95–2.26 0.09
Pelvic lymph node lesions at PSMA-PET imaging (no vs. yes) 1.05 0.69–1.60 0.82
Distant metastases at PSMA-PET imaging
Lymph nodes (no vs. yes) 0.80 0.40–1.60 0.53
Bone (no vs. yes) 0.38 0.24–0.62 0.0001*
Visceral (no vs. yes) 0.19 0.05–0.78 0.02*
Total number of lesions (1 versus > 1) 0.96 0.58–1.59 0.87
Use of additive ADT 2.56 1.51–4.36 0.0005*
PSA, prostate-specific antigen; RP, radical prostatectomy; PSMA-PET, prostate-specific membrane antigen-pos-
itron emission tomography; ADT, androgen deprivation therapy; HR, hazard ratio; 95% CI, 95% confidence
interval
*Significant result
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With these results, we built a risk classification which showed a
convincing internal tenfold cross-validation with 70.6%
accuracy.
Recently, few retrospective series with small patient co-
horts have demonstrated the feasibility and efficacy of
PSMA-PET-guided RT and SBRT [6, 13–18]. Siva et al. pro-
spectively analyzed 33 patients and showed that MDT is a
feasible treatment option [19]. In the recent STOMP phase II
trial, Ost et al. demonstrated prolonged freedom from ADT
with MDT [4]. However, both prospective trials did not use
modern PSMA-PET imaging for staging. To our knowledge,
the present study is the largest retrospective analysis with pa-
tients suffering from oligorecurrent PC treated with PSMA-
PET-guided MDT.
Our classification shows that patients with low PSA levels
(< 0.8 ng/mL) and pelvic lymph node lesions and/or local
recurrence only benefit the most from PSMA-PET-guided
MDT (class I). Patients with PSA level ≥ 0.8 ng/mL and pel-
vic lymph node lesions and/or local recurrence only are at
intermediate risk for treatment failure (class II). Hence, our
data show a favorable outcome for patients treated with
PSMA-PET-guided MDT who are diagnosed with local re-
lapse only. Recently, Schmidt-Hegemann et al. reported a
good response to PSMA-PET-guided salvage RT. The authors
showed a bRFS of 78% after a median follow-up of 23months
for patients with local relapse only [20]. Furthermore, early
treatment of oligorecurrent PC at low PSA levels is desirable.
It remains not surprising that the PSA level before MDT is a
prognostic factor for biochemical relapse. For local salvage
RT, the dictum shifted to “the earlier, the better.” Several stud-
ies have shown that a high pre-treatment PSA level before
local salvage RT is associated with a decreased biochemical
and oncological outcome [21–24]. Early salvage treatment
should be initiated at PSA levels of less than 0.5 ng/mL
[11]. However, data on the prognostic value of pre-PSA level
before MDT in patients with oligorecurrent PC remains rare.
Our data showed a pre-treatment PSA level of 0.8 ng/mL as
the cutoff value. Although this value seems high, treatment of
oligorecurrent PC appears to be beneficial when administered
in patients with PSA levels < 0.8 ng/mL or preferably earlier.
Patients with present bone metastases were at higher risk
for biochemical relapse (class III). However, those patients
still show satisfactory bRFS. Bone metastases are common
in patients with metastatic PC [25]. Muacevic et al. reported
a local control rate of 95.5% at 24 months in patients treated
with robotic SBRT for bone metastases [26]. In a previous
study, Habl et al. showed a local progression-free survival
(PFS) of 100% at 24 months for patients with bone lesions
treated with SBRT. However, the median PSA-PFS was
6.9 months, and the median distant PFS was only 7.4 months
[6]. In our study, in-field local control of bone lesions was
100%; bRFS of patients with bone lesions was 16.0 months.
The limited effectiveness in systemic control in the series of
Habl et al. might be owed to the inability to detect all present
metastatic lesions [6] since the authors staged the patients with
PET imaging using either the [68Ga]PSMAor the [11C]choline
tracer. Therefore, the less sensitive choline-PET imaging
might not have detected all lesions. Although PSMA-PET
imaging shows a massive improvement in sensitivity at low
PSA levels as compared with choline-PET, the detection rate
of recurrences is still approximately 50% at PSA levels below
0.2 ng/mL [27]. Perera et al. reported rates of 58% and 76%
for PSA levels of 0.2–1.0 and 1.0–2.0 ng/mL for PET scans
with [68Ga]PSMA tracers [28]. The optimal threshold value of
PSA indicating a high chance of detection of tumor relapse in
PSMA-PET imaging remains a topic of discussion.
Patients with visceral metastases experience heavily re-
duced bRFS (class IV). Although visceral metastases are not
common in patients with prostate cancer [25], survival is de-
creased in general. Gandaglia et al. reported a reduced median
overall survival (OS) and PC-specific survival (PSS) in pa-
tients with visceral metastases (median OS 16months, median
PSS 26 months) [25]. Only patients with synchronous bone
Table 4 Multiple Cox regression of prognostic factors for biochemical
relapse unadjusted and adjusted for additive androgen deprivation therapy
Factors Multiple Cox regression
unadjusted for ADT
Multiple Cox regression
adjusted for ADT
HR 95% CI p HR 95% CI p
PSA
persistence
> 0.1 ng/-
mL after
RP (yes vs.
no)
1.51 0.98–2.35 0.07 1.78 1.14–2.77 0.011*
PSA level at
PMSA-PE-
T imaging
(> 0.8 ng/-
mL vs.
≤ 0.8 ng/mL)舃0.62舃0.39–0.98舃0.04*
0.50
0.31–0.79
0.003*舃Distant bone metastases at PSMA-PET imaging (no vs. yes)舃
0.39舃0.24–0.64舃0.0002*
2.17
1.33–3.56
0.002*舃Distant visceral metastases at PSMA-PET imaging (no vs.
yes)舃0.09舃0.02–0.38舃0.001*
7.65
1.75–33.44
0.007*舃Use of additive ADT舃–––
3.24
1.87–5.60
0.00002*PSA, prostate-specific antigen; RP, radical prostatectomy;
PSMA-PET, prostate-specific membrane antigen-positron emission
tomography; ADT, androgen deprivation therapy; HR, hazard ratio; 95%
CI, 95% confidence interval
*Significant result
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and visceral metastases showed a worse result (median OS
14 months, median PSS 19 months) [29]. The reduced out-
come was a reason for defining visceral metastases as high-
volume or high-risk disease in the CHAARTED [30] and
LATITUDE [31] trial. The data on MDT for patients with
visceral metastases is still limited. Ost et al. showed no differ-
ence in outcome after MDT between patients with nodal ver-
sus non-nodal metastases as visceral lesions [4]. However, the
study recruited only one patient with visceral lesions.
Although we evaluated a good in-field local control of 100%
in patients with visceral metastases, the systemic effect
seemed suboptimal. Patients developed biochemical relapse
rapidly after local treatment. Therefore, patients with visceral
lesions might exhibit a different, more aggressive tumor biol-
ogy than patients with bone or lymph node metastases. Such
patients might benefit from additional ADT to MDT [32].
However, in such cases, MDT should be discussed individu-
ally. Bearing in mind the reduced bRFS, palliative ADTalone
might be a valid alternative.
Our study has certain limitations. Because of the retro-
spective nature, the management in terms of treatment
was not prospectively defined and differed between insti-
tutions. Administration of additive ADT was not standard-
ized and might be a confounder. To account for this prob-
lem, we calculated a multiple Cox regression unadjusted
and adjusted for additive ADT to show robustness of the
model. Furthermore, RT technique and treatment differed
between institutions with conventional RT on the one
hand to extreme hypofractionated schedules for distant
metastasis on the other hand. This must be considered
when interpreting the results. However, all visible lesions
and thus all the tumor burden was treated with good in-
Fig. 2 Recursive partitioning
analysis (RPA) with the
classification and regression tree
(CRT) method (n = 197, data of
95 patients was censored at
12 months). End nodes are
marked with groups A to E.
(PSMA-PET, prostate-specific
membrane antigen-positron
emission tomography; PSA,
prostate-specific antigen; ng/mL,
nanogram/milliliter)
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field local control (see Table 2). Therefore, influence on bRFS
should be low. The group of patients with visceral metastases
was small. Therefore, the results must be interpreted with
caution. However, the findings are plausible as several studies
show the poor outcome of patients with visceral lesions. The
results will be validated externally for further evidence.
Fig. 3 Kaplan-Meier estimator
for biochemical relapse-free
survival time in months stratified
for risk classes I to IV for the
overall group
Table 5 Risk classes for bRFS after PSMA-PET-guided RT
Risk class RPA group Mean bRFS
(95% CI) in months
Median bRFS
(95% CI) in months
Risk class characteristics
Class I (low risk) Group A 36.3 (32.4–40.1) Not reached PSA level at PSMA-PET imaging
< 0.8 ng/mL, no bone metastases, present
local recurrence, and/or pelvic lymph
nodes only
Class II (intermediate risk) Group B 25.8 (22.5–29.1) 25.0 (18.3–31.7) PSA level at PSMA-PET imaging
≥ 0.8 ng/mL, no bone metastases, no
visceral metastases, present local
recurrence, and/or pelvic lymph nodes only
Class III (high risk) Group C 16.0 (12.4–19.6) 16.0 (6.5–25.5) PSA level at PSMA-PET imaging
< 0.8 ng/mL, present bone metastases
Group D PSA level at PSMA-PET imaging
≥ 0.8 ng/mL, present bone metastases
Class IV (very high risk) Group E 5.7 (2.7–8.7) 7.0 (0.6–13.4) PSA level at PSMA-PET imaging
≥ 0.8 ng/mL, no bone metastases, present
visceral metastases
bRFS, biochemical relapse-free survival; PSMA-PET, prostate-specific membrane antigen-positron emission tomography; PSA, prostate-specific anti-
gen; RPA, recursive partitioning analysis
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Conclusion
We developed a prognostic risk classification for biochemical
relapse after PSMA-PET-guided MDTafter RP with convincing
internal validation. This classificationmight be used to weigh the
risk-benefit ratio of local curative RT for oligorecurrent lesions.
According to this risk classification, patients with PSA levels <
0.8 ng/mL and with local relapse only (local recurrence and/or
pelvic lymph nodes) had the most promising bRFS after MDT.
PSA levels ≥ 0.8 ng/mL and local relapse only (local recurrence
and/or pelvic lymph nodes) indicated intermediate risk for fail-
ure. Patients with bone lesions were at higher risk for failure after
MDT regardless of the PSA level. However, those patients still
show satisfactory bRFS. In patients with visceral metastases,
bRFS is heavily decreased; thus, MDT in such cases should be
discussed individually.
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